The monoclonal antibody secukinumab is approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of six years who are candidates for systemic therapy. The German Institute ...
Dec 4, 2020
0
3
Medications that target tumor necrosis factor alpha (TNFα), a protein involved in inflammation, have revolutionized the management of certain autoimmune diseases, but paradoxically, these agents might provoke the development ...
Jul 3, 2019
0
1
A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.
Jun 12, 2013
0
0
A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...
Apr 29, 2013
0
0
The cost of one year's treatment of rheumatoid arthritis with new generation drugs is more than the per capita gross domestic product of 26 European countries, reveals research published online in the Annals of the Rheumatic ...
Mar 6, 2013
0
0
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional ...
Jun 7, 2012
0
0
(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.
Apr 20, 2012
0
0
